AUPH Q2 2022 Earnings — Aurinia Pharmaceuticals Inc. Revenue & Financial Results | Market Cap Arena

AUPHAurinia Pharmaceuticals Inc.

$2B

Q2 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$28M+325.8% YoY

Gross Profit

$27M94.3% margin

Operating Income

-$36M-127.7% margin

Net Income

-$36M-126.0% margin

EPS (Diluted)

$-0.25

QoQ Revenue Growth

+30.4%

Cash Flow

Operating Cash Flow

-$28M

Free Cash Flow

-$28M

Stock-Based Comp.

$10M

Balance Sheet

Total Assets

$482M

Total Liabilities

$58M

Stockholders' Equity

$424M

Cash & Equivalents

$152M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$28M	$7M	+325.8%
Gross Profit	$27M	$6M	+321.3%
Operating Income	-$36M	-$47M	+23.6%
Net Income	-$36M	-$47M	+24.5%

Revenue Segments

Product

$28M100%

License

$43,0000%